-
3D Medicines’ H1 2023 Report Highlights 70.3% YOY Growth in Envafolimab Sales
•
China-based oncology specialist 3D Medicines (HKG: 1244) has released its financial report for the first half of 2023, highlighting significant revenue generated by envafolimab, a programmed death-ligand 1 (PD-L1) antibody capable of subcutaneous injection. The product has been covered under 32 city-level insurance schemes (HuiMinBao) and has seen rapid uptake,…
-
Acotec Scientific Holdings Receives Japanese Marketing Approval for Peripheral Support Catheter Vericor
•
Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it has received marketing approval from the Ministry of Health, Labour and Welfare of Japan for its peripheral support catheter, Vericor. This approval allows the product to be used in conjunction with a guide wire to…
-
Chime Biologics Partners with Panolos Bioscience to Speed Up Multi-Specific Protein Development
•
China-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics Ltd has announced a strategic cooperation with South Korean biotech firm Panolos Bioscience. The partnership aims to accelerate the development of multi-specific proteins, although no financial details have been disclosed. Focus on Multi-Specific TherapeuticsPanolos Bioscience is a biopharmaceutical company specializing in…
-
Hangzhou Qihan Biotechnology Secures Over $13.8 Million in Pre-Series B Financing
•
Hangzhou Qihan Biotechnology Co., Ltd, a leading xenotransplantation specialist based in China, has reportedly raised over RMB 100 million (USD 13.8 million) in a pre-Series B financing round. The funds will be allocated to support product iteration and global development initiatives over the next four years, marking a significant step…
-
CNIPA Upholds Alynlam Pharmaceutical’s PCSK9 siRNA Patent Against Junshi Biosciences Challenge
•
The China National Intellectual Property Administration (CNIPA) has rejected a challenge filed by Junshi Biosciences (SHA: 688180) against a patent held by Alynlam Pharmaceutical (NASDAQ: ALNY), which is related to the development of PCSK9-targeted small-interfering RNA (siRNA) therapies. CNIPA’s decision to fully maintain Patent No. 561449, associated with application number…
-
Everest Medicines Partners with Kezar Life Sciences to Commercialize Zetomipzomib in Asia
•
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a strategic collaboration and license agreement with US firm Kezar Life Sciences Inc. (NASDAQ: KZR) to develop and commercialize zetomipzomib, Kezar’s novel first-in-class selective immunoproteasome inhibitor, in Greater China, South Korea, and Southeast Asia. This partnership aims to leverage the…
-
I-Mab Regains Global Rights to CD47 Antibody Lemzoparlimab Following AbbVie Deal Termination
•
China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has received a notice from US-based AbbVie Global Enterprises Ltd, announcing the termination of their license and collaboration agreement concerning CD47 antibody compounds and products. The agreement, initially signed on September 3, 2020, and amended on August 15, 2022, will officially end on November…
-
Sanofi’s Dupixent Secures NMPA Approval for Pruritigo Nodosa Treatment in China
•
France-based pharmaceutical company Sanofi (NASDAQ: SNY) has announced that it has received another indication approval from the National Medical Products Administration (NMPA) in China for its drug Dupixent (dupilumab), which is now approved to treat prurigo nodosa (PN) in adults. This makes Dupixent the first and only drug approved for…
